KR910006277A - N-치환된-4-피리미딘아민 및 피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도 - Google Patents

N-치환된-4-피리미딘아민 및 피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도 Download PDF

Info

Publication number
KR910006277A
KR910006277A KR1019900013896A KR900013896A KR910006277A KR 910006277 A KR910006277 A KR 910006277A KR 1019900013896 A KR1019900013896 A KR 1019900013896A KR 900013896 A KR900013896 A KR 900013896A KR 910006277 A KR910006277 A KR 910006277A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
pharmaceutically acceptable
acid addition
acceptable acid
Prior art date
Application number
KR1019900013896A
Other languages
English (en)
Other versions
KR0162641B1 (ko
Inventor
찰스 에플랜드 리챠드
토마스 클레인 조셉
데이비스 래리
에드워드 올센 고돈
Original Assignee
제이 티. 셰크 2세
훽스트-러셀 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이 티. 셰크 2세, 훽스트-러셀 파마슈티컬즈 인코포레이티드 filed Critical 제이 티. 셰크 2세
Publication of KR910006277A publication Critical patent/KR910006277A/ko
Application granted granted Critical
Publication of KR0162641B1 publication Critical patent/KR0162641B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

내용 없음

Description

N-치환된-4-피리미딘아민 및-피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 일반식(Ⅰ)의 화합물과 약제학적으로 허용가능한 이의 산부가염 및 적당하게는 이의 기하학 및 광학 이성체와 라세믹 혼합물.
    상기식에서 R1은 수소, 저급알킬, 알릴 또는 아릴저급알킬이고; R2및 R3는 독립적으로 수소 또는 저급알킬이거나 R2및 R3는 함께 아릴이며; R4및 R5는 독립적으로 수소 또는 저급알킬이거나 R4및 R5가 함께 아릴이고; X는 수소, 할로겐, 시아노, 니트로, 아미노, 저급알킬, 저급알콕시, 트리플루오로메틸 또는
    이며, Y는 수소, 할로겐 또느 저급알킬이고; m은 1 내지 3의 정수이다.
  2. 제1항에 있어서, R1이 수소 또는 저급알킬인 화합물.
  3. 제2항에 있어서, R4및 R5가 함께 페닐인 화합물.
  4. 제1항에 있어서, N-(1H-인돌-1-일)-N-프로필-4-피리미딘아민 또는 이의 약제학적으로 허용 가능한 산부가염인 화합물.
  5. 제1항에 있어서, N-(3-메틸-1H-인돌-1-일)-N-프로필-4-피리미딘아민 또는 이의 약제학적으로 허용 가능한 산부가염인 화합물.
  6. 제1항에 있어서, N-(피리미딘-4-일)-9H-카바졸-9-아민 또는 이의 약제학적으로 허용 가능한 산부가염인 화합물.
  7. 제1항에 있어서, 5-시아노-N-(1H-인돌-1-일)-N-프로필-4-피리미딘아민 또는 이의 약제학적으로 허용 가능한 산부가염인 화합물.
  8. 제1항에 있어서, 6-클로로-N-(1H-인돌-1-일)-N-프로필-4-피리미딘아민 또는 이의 약제학적으로 허용 가능한 산부가염인 화합물.
  9. 제1항에 있어서, 6-클로로-N-(3-메틸-1H-인돌-1-일)-4-피리미딘아민 또는 이의 약제학적으로 허용 가능한 산부가염인 화합물.
  10. 제1항에 있어서, 5-시아노-N-(1H-인돌-1-일)-4-피리미딘아민 또는 이의 약제학적으로 허용 가능한 산부가염인 화합물.
  11. 활성 성분으로서의 제1항에 따른 화합물 및 이를 위해 적절한 담체를 함유하는 약제학적 조성물.
  12. 진통 및/또는 기억 증진활성을 가진 약제의 제조를 위한 제1항에 따른 화합물의 용도.
  13. a) 일반식(Ⅱ)의 화합물과 일반식(Ⅲ)의 화합물을 반응시키고, b) X가 클로로인 일반식(Ⅰ)의 화합물을 임의로 촉매적 수소화시켜 X가 수소인 일반식(Ⅰ)의 합물을 제조하거나, c) X가 할로겐이고 m이 1인 일반식(Ⅱ)의 화합물을 R1이 수소이고 R2및 R3이 함께 페닐이며, R4가 수소이고, R5가 수소 또는 저급알킬인 일반식(Ⅱ)의 화합물 2몰 이상과 임의로 반응시켜 R1이 수소이고, R2및 R3가 함께 페닐이며, R4및 R5가 상기에서 정의한 바와 같고, X가 그룹
    이며, Y가 수소 또는 저급알킬인 일반식(Ⅰ)의 화합물을 제조함을 특징으로 하여, 제1항에 따른 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기식에서 R1내지 R5, X 및 m은 제1항에서 정의한 바와 같고, Hal은 할로겐이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900013896A 1989-09-05 1990-09-04 N-치환된-4-피리미딘 아민 및-피리미딘 디아민 및 이를 포함하는 약제학적 조성물 KR0162641B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/402,415 US4983608A (en) 1989-09-05 1989-09-05 N-substituted-4-pyrimidinamines and pyrimidinediamines
US402,415 1989-09-05
US402415 1989-09-05

Publications (2)

Publication Number Publication Date
KR910006277A true KR910006277A (ko) 1991-04-29
KR0162641B1 KR0162641B1 (ko) 1998-12-01

Family

ID=23591798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900013896A KR0162641B1 (ko) 1989-09-05 1990-09-04 N-치환된-4-피리미딘 아민 및-피리미딘 디아민 및 이를 포함하는 약제학적 조성물

Country Status (18)

Country Link
US (1) US4983608A (ko)
EP (1) EP0417584B1 (ko)
JP (1) JPH07116181B2 (ko)
KR (1) KR0162641B1 (ko)
AT (1) ATE163012T1 (ko)
AU (1) AU626450B2 (ko)
CA (1) CA2024572C (ko)
DE (1) DE69032020T2 (ko)
DK (1) DK0417584T3 (ko)
ES (1) ES2112830T3 (ko)
FI (1) FI904327A0 (ko)
GR (1) GR3026318T3 (ko)
IE (1) IE903213A1 (ko)
IL (1) IL95568A (ko)
NO (1) NO903851L (ko)
NZ (1) NZ235145A (ko)
PT (1) PT95202B (ko)
ZA (1) ZA907033B (ko)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5319096A (en) * 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
AU726058B2 (en) * 1995-09-01 2000-10-26 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
ZA989365B (en) 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
CN1297447A (zh) 1998-02-17 2001-05-30 图拉列克股份有限公司 抗病毒嘧啶衍生物
AU5438499A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
JP2002523497A (ja) * 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ES2306671T3 (es) * 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
US6410726B1 (en) 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1490354A1 (en) * 2002-03-09 2004-12-29 Astrazeneca AB 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
CN1678321A (zh) * 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP1656372B1 (en) * 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
BRPI0510980A (pt) * 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento do crescimento anormal de células
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
CA2566477A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2578349A1 (en) * 2004-09-01 2006-03-16 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
ATE540035T1 (de) * 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
WO2006064251A1 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
MX2008001428A (es) * 2005-07-30 2008-04-04 Astrazeneca Ab Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
JP2009512636A (ja) * 2005-09-30 2009-03-26 アストラゼネカ アクチボラグ 細胞増殖抑制作用を有するイミダゾ［１，２−ａ］ピリジン類
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
BRPI0810199A2 (pt) 2007-04-13 2014-10-14 Sanofi Aventis Síntese catalisada por metal de transição de n-aminoindóis
GB2553716B (en) * 2015-04-17 2020-06-17 Univ Holy Ghost Duquesne Pyrrolopyrimidines as antitumor agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752610A (en) * 1985-12-04 1988-06-21 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing properties
US4792562A (en) * 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
ES2065324T3 (es) * 1987-04-24 1995-02-16 Hoechst Roussel Pharma N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos.
US4806554A (en) * 1988-01-11 1989-02-21 Hoechst-Roussel Pharmaceuticals, Inc. Pyrazol and indazolpyridinamines
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines

Also Published As

Publication number Publication date
ATE163012T1 (de) 1998-02-15
EP0417584B1 (en) 1998-02-04
IE903213A1 (en) 1991-03-13
US4983608A (en) 1991-01-08
AU6208990A (en) 1991-03-14
EP0417584A3 (en) 1992-02-26
ZA907033B (en) 1991-06-26
KR0162641B1 (ko) 1998-12-01
EP0417584A2 (en) 1991-03-20
DE69032020D1 (de) 1998-03-12
NO903851D0 (no) 1990-09-04
NO903851L (no) 1991-03-06
DE69032020T2 (de) 1998-07-09
JPH0393784A (ja) 1991-04-18
CA2024572A1 (en) 1991-03-06
NZ235145A (en) 1992-12-23
AU626450B2 (en) 1992-07-30
PT95202B (pt) 1997-06-30
IL95568A (en) 1995-01-24
CA2024572C (en) 2000-09-26
ES2112830T3 (es) 1998-04-16
DK0417584T3 (da) 1998-09-23
PT95202A (pt) 1991-05-22
IL95568A0 (en) 1991-06-30
GR3026318T3 (en) 1998-06-30
JPH07116181B2 (ja) 1995-12-13
FI904327A0 (fi) 1990-09-03

Similar Documents

Publication Publication Date Title
KR910006277A (ko) N-치환된-4-피리미딘아민 및 피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도
ATE247654T1 (de) Neue heterozyklische verbindungen
RU96115142A (ru) Производные 5-(2-имидазолиниламино)бензимидазола, их получение и применение в качестве агонистов альфа-2-адреноцепторов
KR920006314A (ko) 아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR880002834A (ko) α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도
KR910000707A (ko) 헤테로아릴아미노-및 헤테로아릴옥시피리딘아민 및 관련 화합물, 이의 제조방법 및 약제로서의 이의 용도
KR930019667A (ko) 항-종양 화합물
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
KR910004599A (ko) 1,3-디하이드로-1-(피리디닐아미노)-2h-인돌-2-온, 이들의 제조방법 및 이들의 약제로서의 용도
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
KR900014388A (ko) 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도
KR890016017A (ko) 치환된 1-(1h-이미다졸-4-일)알킬-벤즈아미드
KR890005036A (ko) 아미드화합물, 이들의 제조방법 및 이들 화합물을 함유하여 위신경기능을 활성화하는 조성물
KR910004597A (ko) 1-(피리디닐아미노)-2-피롤리디논, 이의 제조방법 및 약제로서의 이의 용도
KR880011112A (ko) 벤즈아제핀 설폰아미드 화합물
KR920007995A (ko) 벤즈아미드 유도체
KR910004598A (ko) 2,3-디하이드로-1-(피리디닐아미노)-인돌, 이의 제조방법 및 약제로서 이의 용도
RU2205829C2 (ru) Замещенное производное циклобутиламина, антибактериальный агент и фармацевтическая композиция на его основе
KR900009596A (ko) N-피리디닐-9h-카바졸-9-아민, 이의 제조방법 및 이의 약제로서의 용도
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
KR920006346A (ko) 3-(1h-인다졸-3-일)-4-피리딘아민, 이의 제조방법, 이의 제조를 위한 중간체 및 약제로서의 이의 용도
ATE56967T1 (de) Amidderivate.
KR910000744A (ko) 4,5,5a,6-테트라하이드로-3H-이속사졸로[5,4,3-kl]아크리딘 유도체, 이의 제조 방법 및 약제로서의 이의 용도
KR960004363A (ko) 피리미딘 아사이클로뉴클레오시드 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100825

Year of fee payment: 13

EXPY Expiration of term